You can buy or sell PGNX and other stocks, options, ETFs, and crypto commission-free!
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. Read More The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Seeking AlphaMar 14
Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Baker on Q4 2018 Results - Earnings Call Transcript
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Q4 2018 Earnings Conference Call March 14, 2019 8:30 AM ET Company Participants Melissa Downs - Associate Director, Investor Relations Mark Baker - Chief Executive Officer Bryce Tenbarge - Senior Vice President of Commercial Pat Fabbio - Executive Vice President & Chief Financial Officer Conference Call Participants Martin Auster - Credit Suisse Chad Messer - Needham & Company Tim Chiang - BTIG Biren Amin - Jefferies Operator Good day, ladies and gen...
Yahoo FinanceMar 14
Progenics (PGNX) Reports Q4 Loss, Misses Revenue Estimates
Retrophin (RTRX) delivered earnings and revenue surprises of -10.53% and -0.98%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Simply Wall StFeb 23
Is Progenics Pharmaceuticals, Inc.’s (NASDAQ:PGNX) CEO Pay Fair?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! In 2011 Mark Baker was appointed CEO of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that the business demonstrates. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. The aim of all this is t...
-$0.11 per share
-$0.17 per share